Introgen And R-PR Gene Therapy Deal
Introgen Therapeutics has entered into a strategic agreement with Rhone-Poulenc Rorer to develop and commercialize gene therapy cancer products based on the p53 pathway and K-ras inhibition. Rhone-Poulenc Rorer will fund all research and development worldwide and will receive exclusive manufacturing and commercial rights in Europe.
Introgen and R-PR have co-promotion rights in North America and both companies have the right to develop and market products in Japan, Korea, India, China and Australia. Introgen will retain manufacturing rights in North America.
The transaction includes an equity position for R-PR and comes just prior to Introgen's commencement of two Phase I clinical studies of its in vivo gene therapy products for lung cancer. The deal has a potential value to Introgen of up to $50 million consisting of equity, research and development and milestone payments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze